OBJECTIVES: The objective of this research was to estimate the 5-year financial impact of adding finerenone to the hospital formulary of a tertiary hospital in Riyadh, Saudi Arabia.

METHODS: Budget impact analysis (BIA) was performed from a payer perspective: Tertiary hospital in Riyadh, Saudi Arabia. Costs of Finerenone was calculated for patients with an average duration of treatment 52 weeks. The target population was determined using hospital statistical data, and clinical evaluation data

RESULTS: Over 5 years after the addition of the drug to the hospital formulary and from the health care payer perspective “pharmacy budget", we estimated the minimum population eligible for treatment to be 62 in all 5 years, with an estimated uptake rate of 50 % in year 1 and 100% in year 5. The gross impact on the pharmacy budget was estimated to be SAR 478,800.00 in year 1 and SAR 976,752.00 in year 5.The standard of care therapy including Dapagliflozin,Furosemide, Candesartan Cilexetil, and Lisinopril were assumed to be an alternative; the net medicines budget impact is expected to be SAR 77,522.00 in year 1 and SAR 158,144.00 in year 5.

CONCLUSIONS: In a Saudi Practice setting, the addition of finerenone to hospital formulary is associated with substantially increased costs .Standard of care therapy could be a better formulary option from a pharmacy budget prespective.